Browse drugs

…afibranor initiation. 2 (7.4%) patients continued OCA alongside elafibranor. 19 (70.4%) patients had trialled bezafibrate prior to elafibra…

…eoporosis in both groups, particularly in patients who received elafibranor. Imbalances were also seen in the underlying medical history fo…

…0.26–0.33), and they could improve independently of one another.Elafibranor resulted in clinically meaningful improvements in fatigue, with…

…nor arm were –41.5% (26.7), –41.8% (23.0) and –32.3% (22.3) for elafibranor in the healthy weight, overweight and obese subgroups respectiv…

…ammation, fibrosis, and destruction of intrahepatic bile ducts. Elafibranor, a peroxisome proliferator-activated receptor (PPAR) agonist ex…

…Elafibranor is a dual PPAR-α/δ agonist recently licenced for treatment of P…

…a. TB, ALT, AST and ALB were relatively stable in both subsets. Elafibranor was well-tolerated in this subset to Week 104.With two years of…

…% CI 23.7 – 50.3)) SELADELPAR (ARR = 40.9 (95% CI 28.1 – 53.8)) ELAFIBRANOR (ARR = 47.2 (95% CI 36.4 – 57.9)) ARR = 10.2 (-6.9 ; 27,3) p = …

…Introduction Elafibranor (ELA) led to significant biochemical improvements in patients w…

…py, while 27% were prescribed second-line treatments, including Bezafibrate (31 patients), Obeticholic acid (20 patients), and Elafibranor …

…pleted the DBP, 63 (98.4%) entered the OLE; 22 (100%) continued ELA 120mg treatment, and 20 (95.2%) and 21 (100%) crossed over from…

…UDCA), obeticholic acid (OCA), and amongst those switching from bezafibrate (BZF).Results From Dec 2024 to Nov 2025, 54 pts initiated Ela (…